Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BullsEye Study of vedolizumab response biomarkers in Crohn's disease
NL-OMON50386Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of vedolizumab in Crohn's disease, sponsored by University Medical Center Utrecht. Started Dec 2017; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON50386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50386.